338 related articles for article (PubMed ID: 26751790)
1. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
Zhou H; Lu Y; Wu B; Che D
J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma.
Zein JG; Menegay MC; Singer ME; Erzurum SC; Gildea TR; Cicenia JC; Khatri S; Castro M; Udeh BL
J Asthma; 2016; 53(2):194-200. PubMed ID: 26377375
[TBL] [Abstract][Full Text] [Related]
7. Is bronchial thermoplasty cost-effective as treatment for problematic asthma patients? Singapore's perspective on a global model.
Nguyen HV; Bose S; Mital S; Yii ACA; Ang SY; Lam SSW; Anantham D; Finkelstein E; Koh MS
Respirology; 2017 Aug; 22(6):1102-1109. PubMed ID: 28370985
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.
Wilson EC; Price D; Musgrave SD; Sims EJ; Shepstone L; Murdoch J; Mugford HM; Blyth A; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Hillyer EV; Harvey I
Pharmacoeconomics; 2010; 28(7):597-608. PubMed ID: 20446755
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.
Zafari Z; Sadatsafavi M; Mark FitzGerald J;
Cost Eff Resour Alloc; 2018; 16():3. PubMed ID: 29422778
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
13. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma.
Buendia JA; Guerrero Patiño D; Cossio-Giraldo YE
J Asthma; 2022 Oct; 59(10):2016-2023. PubMed ID: 34551659
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
Brown R; Turk F; Dale P; Bousquet J
Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
[TBL] [Abstract][Full Text] [Related]
16. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
FitzGerald JM; Arnetorp S; Smare C; Gibson D; Coulton K; Hounsell K; Golam S; Sadatsafavi M
Respir Med; 2020 Sep; 171():106079. PubMed ID: 32917353
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
